Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53
doi: 10.2337/dc16-0406 34 FerranniniE
However, at 12 months, weight gain was primarily associated with endocrine therapy (tamoxifen or aromatase inhibitor) with patients gaining 2.36 kg on average compared to those not on endocrine therapy, indicating that this treatment could have impacted weight loss for patients on GLP1 RAs
Nutr Rep Internat 1984;29:1071-1079
Conclusion In this network meta-analysis, tirzepatide was associated with significant reductions in MACE, CV mortality, all-cause mortality, non-fatal MI, and non-fatal stroke compared with placebo in the class-level analysis
The body can be protected from these free radicals with antioxidants